Mar 4 |
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
|
Mar 1 |
Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX)
|
Feb 29 |
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
|
Feb 26 |
MoonLake gets FDA, EMA feedback on Phase 3 study
|
Feb 26 |
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
|
Feb 26 |
MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3
|
Feb 21 |
Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics
|
Jan 11 |
Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade
|
Jan 10 |
Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?
|